JP2018500394A5 - - Google Patents

Download PDF

Info

Publication number
JP2018500394A5
JP2018500394A5 JP2017550467A JP2017550467A JP2018500394A5 JP 2018500394 A5 JP2018500394 A5 JP 2018500394A5 JP 2017550467 A JP2017550467 A JP 2017550467A JP 2017550467 A JP2017550467 A JP 2017550467A JP 2018500394 A5 JP2018500394 A5 JP 2018500394A5
Authority
JP
Japan
Prior art keywords
plga
polymer
sunitinib
peg
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017550467A
Other languages
English (en)
Other versions
JP6847848B2 (ja
JP2018500394A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/065878 external-priority patent/WO2016100380A1/en
Publication of JP2018500394A publication Critical patent/JP2018500394A/ja
Publication of JP2018500394A5 publication Critical patent/JP2018500394A5/ja
Application granted granted Critical
Publication of JP6847848B2 publication Critical patent/JP6847848B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (24)

  1. 両親媒性ポリマー及び/又は1つ以上の疎水性ポリマーのブレンド中に封入又は分散されたスニチニブ又はその薬学的に許容可能な塩を含む、眼圧上昇による眼の神経損傷の低減への使用のためのポリマーミクロ粒子。
  2. 前記疎水性ポリマーがポリ乳酸及び/又は乳酸とグリコール酸とのコポリマーを含む、請求項1に記載のポリマーミクロ粒子。
  3. 前記両親媒性ポリマーがペグ化疎水性ポリマーを含む、請求項1又は2に記載のポリマーミクロ粒子。
  4. 前記疎水性ポリマーがポリ(ラクチド−co−グリコリド)(PLGA)であり、前記両親媒性ポリマーがポリエチレングリコール(PEG)に結合したPLGAであり、
    任意に約1ミクロン〜50ミクロンの平均径と約10重量%以上のスニチニブ又はその薬学的に許容可能な塩の重量装荷を有する、
    請求項1〜3のいずれか一項に記載のポリマーミクロ粒子。
  5. 約1ミクロン〜50ミクロンの平均径を有する、請求項1〜3のいずれか一項に記載のポリマーミクロ粒子。
  6. 前記スニチニブ又はその薬学的に許容可能な塩が約5重量%超の量で存在する、請求項1〜3及び5のいずれか一項に記載のポリマーミクロ粒子。
  7. 前記PLGA及びPLGA−PEGが約99重量%のPLGAと1重量%のPLGA−PEGとの混合物で存在する、請求項4に記載のポリマーミクロ粒子。
  8. 前記PLGA−PEGコポリマーが分子量およそ45kDaのPLGA及び分子量およそ5kDaのPEGから形成される、請求項7に記載のポリマーミクロ粒子。
  9. 前記スニチニブ又はその薬学的に許容可能な塩が、両親媒性ポリマーと1種よりも多い疎水性ポリマーとのブレンド中に封入される、請求項1〜3及び5〜6のいずれか一項に記載のポリマーミクロ粒子。
  10. 少なくとも約10重量%以上のスニチニブ又はその薬学的に許容可能な塩を含み、約1ミクロン〜50ミクロンの平均径、好ましくは約1ミクロン〜30ミクロンの平均径を有するミクロ粒子を含む、眼圧上昇による眼の神経損傷の低減への使用のための組成物。
  11. 前記スニチニブ又はその薬学的に許容可能な塩が少なくとも約15重量%の量でミクロ粒子中に封入される、請求項10に記載の組成物。
  12. 前記ミクロ粒子がポリ(ラクチド−co−グリコリド)(PLGA)と、ポリ(ラクチド−co−グリコリド)−ポリエチレングリコール(PLGA−PEG)とのブレンド、好ましくは約99重量%のPLGAと1重量%のPLGA−PEGとの混合物を含む、請求項10〜11のいずれか一項に記載の組成物。
  13. 前記PLGA−PEGコポリマーが分子量およそ45kDaのPLGAと分子量およそ5kDaのPEGとを有する、請求項12に記載の組成物。
  14. 前記ミクロ粒子が少なくとも3ヶ月の持続期間に亘ってスニチニブを眼の硝子体腔に放出する、請求項10〜13のいずれか一項に記載の組成物。
  15. 前記スニチニブはアルカリ性溶媒系から得られ、任意に前記スニチニブはリンゴ酸塩の形態で存在する、請求項1〜9のいずれか一項に記載のポリマーミクロ粒子。
  16. 前記スニチニブはアルカリ性溶媒系から得られ、任意に前記スニチニブはリンゴ酸塩の形態で存在する、請求項10〜14のいずれか一項に記載の組成物。
  17. 1ミクロン〜50ミクロンの平均径を有し、PLGAとPLGA−PEGとのブレンド中に封入された5重量%超のスニチニブ又はその薬学的に許容可能な塩を含み、少なくとも2週間に亘って前記スニチニブを放出する、眼圧上昇による患者の眼の神経損傷の低減への使用のためのポリマーミクロ粒子。
  18. 前記患者がヒトである、請求項17に記載のポリマーミクロ粒子。
  19. 前記PLGAと前記PLGA−PEGが、約99重量%のPLGAと1重量%のPLGA−PEGとの混合物中に存在する、請求項17又は18に記載のポリマーミクロ粒子。
  20. さらにPLAを含む、請求項17〜19のいずれか一項に記載のポリマーミクロ粒子。
  21. 前記薬学的に許容可能な塩がリンゴ酸スニチニブである、請求項17〜20のいずれか一項に記載のポリマーミクロ粒子。
  22. 1ミクロン〜30ミクロンの平均径を有する、請求項17〜21のいずれか一項に記載のポリマーミクロ粒子。
  23. 硝子体内注射により投与される、請求項17〜22のいずれか一項に記載のポリマーミクロ粒子。
  24. 結膜下注射により投与される、請求項17〜22のいずれか一項に記載のポリマーミクロ粒子。
JP2017550467A 2014-12-15 2015-12-15 スニチニブ製剤、及び緑内障の治療におけるその使用方法 Active JP6847848B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462092118P 2014-12-15 2014-12-15
US62/092,118 2014-12-15
US201562139306P 2015-03-27 2015-03-27
US62/139,306 2015-03-27
PCT/US2015/065878 WO2016100380A1 (en) 2014-12-15 2015-12-15 Sunitinib formulations and methods for use thereof in treatment of glaucoma

Publications (3)

Publication Number Publication Date
JP2018500394A JP2018500394A (ja) 2018-01-11
JP2018500394A5 true JP2018500394A5 (ja) 2019-01-31
JP6847848B2 JP6847848B2 (ja) 2021-03-24

Family

ID=55069169

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017550469A Active JP6882186B2 (ja) 2014-12-15 2015-12-15 スニチニブ製剤及び眼の障害の治療におけるその使用に対する方法
JP2017550467A Active JP6847848B2 (ja) 2014-12-15 2015-12-15 スニチニブ製剤、及び緑内障の治療におけるその使用方法
JP2021078406A Pending JP2021119183A (ja) 2014-12-15 2021-05-06 スニチニブ製剤及び眼の障害の治療におけるその使用に対する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017550469A Active JP6882186B2 (ja) 2014-12-15 2015-12-15 スニチニブ製剤及び眼の障害の治療におけるその使用に対する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021078406A Pending JP2021119183A (ja) 2014-12-15 2021-05-06 スニチニブ製剤及び眼の障害の治療におけるその使用に対する方法

Country Status (19)

Country Link
US (4) US20170273901A1 (ja)
EP (2) EP3233058A1 (ja)
JP (3) JP6882186B2 (ja)
KR (2) KR20170094793A (ja)
CN (3) CN107278151A (ja)
AU (2) AU2015362621B2 (ja)
BR (1) BR112017012706A2 (ja)
CA (1) CA2972075C (ja)
CO (1) CO2017007003A2 (ja)
EA (1) EA201791337A1 (ja)
HK (1) HK1243942A1 (ja)
IL (1) IL252943A0 (ja)
MX (1) MX2017007873A (ja)
NZ (1) NZ733130A (ja)
PH (1) PH12017501097A1 (ja)
RU (1) RU2729731C2 (ja)
SG (2) SG10201903210WA (ja)
WO (2) WO2016100392A1 (ja)
ZA (1) ZA201703875B (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016100392A1 (en) * 2014-12-15 2016-06-23 The Johns Hopkins University Sunitinib formulations and methods for use thereof in treatment of ocular disorders
BR112018005589A2 (pt) 2015-09-22 2018-10-09 Graybug Vision Inc “composto, composição farmaceuticamente aceitável, e, uso de um composto”
CA3004886A1 (en) * 2015-11-12 2017-05-18 Graybug Vision, Inc. Aggregating microparticles for medical therapy
BR112019019452A2 (pt) 2017-03-23 2020-04-14 Graybug Vision Inc composto, e, uso de um composto
WO2018182527A1 (en) * 2017-03-30 2018-10-04 National University Of Singapore Method for treating inflammatory complications in eye diseases
WO2018209155A1 (en) 2017-05-10 2018-11-15 Graybug Vision, Inc. Extended release microparticles and suspensions thereof for medical therapy
WO2019016686A1 (en) * 2017-07-17 2019-01-24 Wolfcreek Biotech Pte Ltd MICROPARTICLE FORMULATIONS FOR THE ADMINISTRATION OF ACTIVE AGENTS
US20210113664A1 (en) * 2018-06-25 2021-04-22 Titan Pharmaceuticals, Inc. Implants for release of lipophilic or amphiphilic pharmaceutical substances
CN112566625A (zh) * 2018-08-18 2021-03-26 夫特弗制药私人有限公司 口服剂量的化学治疗药物悬浮液
WO2020069353A1 (en) * 2018-09-27 2020-04-02 Graybug Vision, Inc. Compounds and compositions for ocular delivery
CN110946858A (zh) * 2018-09-27 2020-04-03 中国科学院上海生命科学研究院 吲哚满酮衍生物在治疗肥胖及其相关疾病中的应用
KR102308227B1 (ko) * 2018-10-31 2021-10-05 주식회사 삼양홀딩스 수니티닙을 함유하는 경구용 정제 조성물
KR102322429B1 (ko) * 2018-10-31 2021-11-08 주식회사 삼양홀딩스 수니티닙을 함유하는 경구용 제제 및 그의 제조 방법
WO2020102758A1 (en) * 2018-11-15 2020-05-22 Graybug Vision, Inc. Improved aggregated microparticles
WO2020222541A1 (ko) * 2019-04-30 2020-11-05 주식회사 엘지화학 캐스파제 저해제의 프로드럭
US11471412B1 (en) * 2019-05-10 2022-10-18 University Of South Florida Nanoparticles and nanogel drug compositions for treatment of age-related macular degeneration
CN110833425B (zh) * 2019-11-27 2022-12-30 佛山科学技术学院 一种用于鸡胚采血的血管托持器
KR20240025990A (ko) * 2022-08-19 2024-02-27 주식회사 스카이테라퓨틱스 무정형 수니티닙, 그 제조방법 및 이를 포함한 의약 조성물
KR20240028815A (ko) 2022-08-25 2024-03-05 주식회사 스카이테라퓨틱스 약리 활성 물질의 신규 분자회합체 및 이를 포함하는 약학 조성물
WO2024095026A1 (en) 2022-11-04 2024-05-10 Semmelweis Egyetem In vivo targeting of therapeutic molecules to the retina via the optical system of the eye

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB929401A (en) 1958-12-22 1963-06-19 Upjohn Co Encapsulated emulsions and processes for their preparation
GB929405A (en) 1958-12-22 1963-06-19 Upjohn Co Processes for the encapsulation of particles
GB969808A (en) 1962-06-08 1964-09-16 Boots Pure Drug Co Ltd Anthelmintic compositions and compounds
IT1148784B (it) 1980-04-09 1986-12-03 Eurand Spa Procedimento per la preparazione di microcapsule in un veicolo liquido
US4794000A (en) 1987-01-08 1988-12-27 Synthetic Blood Corporation Coacervate-based oral delivery system for medically useful compositions
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US4991920A (en) 1988-12-27 1991-02-12 Andrzej Peczalski Optical converter
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5565215A (en) * 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US5441722A (en) 1994-02-18 1995-08-15 Merck & Co., Inc. Short synthesis of 5,6-dihydro-(S)-4-(ethylamino)-(S)-6-[C3 H3 ]-4[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide and related non radioactive compounds
GB9412273D0 (en) 1994-06-18 1994-08-10 Univ Nottingham Administration means
US6007845A (en) * 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
CA2207961A1 (en) 1995-01-05 1996-07-11 Robert J. Levy Surface-modified nanoparticles and method of making and using same
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6841617B2 (en) 2000-09-28 2005-01-11 Battelle Memorial Institute Thermogelling biodegradable aqueous polymer solution
US6703047B2 (en) 2001-02-02 2004-03-09 Incept Llc Dehydrated hydrogel precursor-based, tissue adherent compositions and methods of use
US6632457B1 (en) 1998-08-14 2003-10-14 Incept Llc Composite hydrogel drug delivery systems
US6818018B1 (en) 1998-08-14 2004-11-16 Incept Llc In situ polymerizable hydrogels
EP1137373A4 (en) 1998-12-04 2004-05-19 Chandrashekhar P Pathak BIOCOMPATIBLE, CROSSLINKED POLYMERS
US20040258763A1 (en) 1999-02-03 2004-12-23 Bell Steve J.D. Methods of manufacture and use of calcium phosphate particles containing allergens
US6217895B1 (en) 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6287588B1 (en) 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
US6589549B2 (en) 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6706289B2 (en) 2000-10-31 2004-03-16 Pr Pharmaceuticals, Inc. Methods and compositions for enhanced delivery of bioactive molecules
GB0122318D0 (en) 2001-09-14 2001-11-07 Novartis Ag Organic compounds
US20040086532A1 (en) 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
US7060299B2 (en) 2002-12-31 2006-06-13 Battelle Memorial Institute Biodegradable microparticles that stabilize and control the release of proteins
WO2004084819A2 (en) * 2003-03-19 2004-10-07 University Of Kentucky Research Foundation Poly(acryloyl-hydroxyethyl starch)-plga composite microspheres
GB0307011D0 (en) 2003-03-27 2003-04-30 Regentec Ltd Porous matrix
PL1635875T3 (pl) 2003-06-26 2009-03-31 Psivida Inc System dostarczania leków poprzez żelowanie w warunkach in-situ
US20090148527A1 (en) 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
WO2005072710A2 (en) 2004-01-28 2005-08-11 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
ES2246694B1 (es) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Nanoparticulas pegiladas.
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US20050244472A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US7501179B2 (en) 2005-12-21 2009-03-10 Boston Scientific Scimed, Inc. Block copolymer particles
US20070149593A1 (en) 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
CA2636716C (en) 2006-01-13 2014-12-23 Surmodics, Inc. Microparticle containing matrices for drug delivery
US20080166411A1 (en) 2006-04-10 2008-07-10 Pfizer Inc Injectable Depot Formulations And Methods For Providing Sustained Release Of Poorly Soluble Drugs Comprising Nanoparticles
EP2061433B1 (en) 2006-09-08 2011-02-16 Johns Hopkins University Compositions for enhancing transport through mucus
GB0619869D0 (en) 2006-10-07 2006-11-15 Regentec Ltd Porous particles
MX2009004856A (es) 2006-11-09 2009-06-05 Alcon Res Ltd Matriz polimerica insoluble en agua para suministro de farmaco.
GB0701896D0 (en) 2007-02-01 2007-03-14 Regentec Ltd Composition
EP2121057A4 (en) 2007-02-06 2012-10-10 Incept Llc POLYMERIZATION WITH PRECIPITATION OF PROTEINS FOR ELUTION IN A PHYSIOLOGICAL SOLUTION
EP2178502A2 (en) 2007-06-21 2010-04-28 Yale University Sustained delivery of drugs from biodegradable polymeric microparticles
CN101081206A (zh) * 2007-06-29 2007-12-05 济南康泉医药科技有限公司 一种含酪氨酸激酶抑制剂的抗癌药物组合物
US9125807B2 (en) 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
AU2008315318B2 (en) 2007-10-26 2014-02-06 National Institute Of Immunology Biodegradable polymer scaffold and process for preparation thereof
US20090203709A1 (en) 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
CA2717133C (en) 2008-02-29 2016-04-26 Nagoya Industrial Science Research Institute Liposome for delivery to posterior segment of eye and pharmaceutical composition for disease in posterior segment of eye
CN101336890A (zh) 2008-05-30 2009-01-07 济南基福医药科技有限公司 一种抗癌缓释凝胶注射剂
WO2010017541A2 (en) * 2008-08-08 2010-02-11 The Johns Hopkins University Compositions and methods for treatment of neurodegenerative disease
WO2010030739A1 (en) 2008-09-10 2010-03-18 Abbott Laboratories Polyethylene glycol lipid conjugates and uses thereof
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
RU2532345C2 (ru) 2009-01-12 2014-11-10 Хадасит Медикэл Рисёч Сервисес Энд Девелопмент Лимитэд Мембрана для регенерации ткани
JP5577354B2 (ja) 2009-01-29 2014-08-20 フォーサイト・ビジョン フォー・インコーポレーテッド 治療装置
WO2010091187A2 (en) 2009-02-04 2010-08-12 The Brigham And Women's Hospital, Inc. Polymeric nanoparticles with enhanced drug-loading and methods of use thereof
AU2010213612B2 (en) 2009-02-12 2015-04-30 Incept, Llc Drug delivery through hydrogel plugs
MX2011008731A (es) 2009-03-03 2011-09-29 Alcon Res Ltd Composicion farmaceutica para el suministro de compuestos inhibidores de la tirosina cinasa receptora (rtki) para los ojos.
GB0903810D0 (en) 2009-03-05 2009-04-22 Regentec Ltd Delivery system
WO2010114770A1 (en) 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
AU2010340067B2 (en) 2009-12-15 2015-03-19 Incept, Llc Implants and biodegradable fiducial markers
US8889193B2 (en) * 2010-02-25 2014-11-18 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
US20130071349A1 (en) 2010-03-02 2013-03-21 Allergan, Inc. Biodegradable polymers for lowering intraocular pressure
WO2011119777A2 (en) * 2010-03-23 2011-09-29 The Johns Hopkins University Compositions and methods for treatment of neurodegenerative disease
WO2011119995A2 (en) * 2010-03-26 2011-09-29 Cerulean Pharma Inc. Formulations and methods of use
US10307372B2 (en) 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
US8961501B2 (en) 2010-09-17 2015-02-24 Incept, Llc Method for applying flowable hydrogels to a cornea
US20120121718A1 (en) 2010-11-05 2012-05-17 The Johns Hopkins University Compositions and methods relating to reduced mucoadhesion
US9327037B2 (en) 2011-02-08 2016-05-03 The Johns Hopkins University Mucus penetrating gene carriers
WO2012112674A2 (en) * 2011-02-15 2012-08-23 The Johns Hopkins University Compounds and methods of use thereof for treating neurodegenerative disorders
US10226417B2 (en) 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
CN103127096B (zh) * 2011-12-02 2015-11-25 杨子娇 吡咯基取代的吲哚类化合物在治疗青光眼病的应用
KR20190090048A (ko) 2011-12-05 2019-07-31 인셉트, 엘엘씨 의료용 유기젤 방법 및 조성물
AU2012351994B2 (en) 2011-12-14 2015-11-05 The Johns Hopkins University Nanoparticles with enhanced mucosal penetration or decreased inflammation
US9415020B2 (en) 2012-01-19 2016-08-16 The Johns Hopkins University Nanoparticle formulations with enhanced mucosal penetration
AU2013232300B2 (en) 2012-03-16 2015-12-17 The Johns Hopkins University Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
WO2013138343A1 (en) 2012-03-16 2013-09-19 The Johns Hopkins University Controlled release formulations for the delivery of hif-1 inhibitors
US20140107025A1 (en) 2012-04-16 2014-04-17 Jade Therapeutics, Llc Ocular drug delivery system
AU2013256130B2 (en) 2012-05-03 2017-12-21 Alcon Inc. Pharmaceutical nanoparticles showing improved mucosal transport
CN111700879A (zh) 2012-05-03 2020-09-25 卡拉制药公司 显示提高的粘膜转移的药物纳米粒子
US9533068B2 (en) 2012-05-04 2017-01-03 The Johns Hopkins University Drug loaded microfiber sutures for ophthalmic application
AU2013256008B2 (en) 2012-05-04 2016-02-25 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
US9539259B2 (en) * 2012-05-23 2017-01-10 The Johns Hopkins University Compounds and methods of use thereof for treating neurodegenerative disorders
JP2017512748A (ja) * 2012-06-25 2017-05-25 バイエル・ヘルスケア・エルエルシーBayer HealthCare LLC スニチニブを含んでいる眼科用局所医薬組成物
WO2014043625A1 (en) * 2012-09-17 2014-03-20 Bind Therapeutics, Inc. Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
CN103848985B (zh) * 2012-11-30 2018-03-02 杨子剑 含有舒尼替尼类似物结构的新化合物以及制备方法和用途
RU2015146211A (ru) 2013-04-01 2017-05-19 Аллерган, Инк. Микросферная система доставки лекарственного средства для замедленного внутриглазного высвобождения
CN104208715B (zh) 2013-05-31 2016-12-28 天津键凯科技有限公司 具有提高的药物生物活性的低分子量聚乙二醇药物结合物
WO2014203816A1 (ja) 2013-06-18 2014-12-24 昭和電工株式会社 コンデンサ陽極体およびその製造方法
US10646027B2 (en) 2013-08-29 2020-05-12 Sayeeda Mazed Multifunctional personal care devices/apparatuses and compositions for hair or skin
WO2015095772A2 (en) 2013-12-20 2015-06-25 Emory University Formulations and methods for targeted ocular delivery of therapeutic agents
KR101564401B1 (ko) 2014-04-10 2015-11-02 한국화학연구원 브린졸아마이드의 제조방법
EP3193827A1 (en) 2014-08-13 2017-07-26 The Johns Hopkins University Glucocorticoid-loaded nanoparticles for prevention of corneal allograft rejection and neovascularization
US20160106587A1 (en) 2014-10-16 2016-04-21 Incept, Llc Ocular gels or hydrogels and microinjectors
WO2016065245A1 (en) 2014-10-24 2016-04-28 Incept, Llc Extra luminal scaffold
JP7092502B2 (ja) 2014-12-10 2022-06-28 インセプト・リミテッド・ライアビリティ・カンパニー ハイドロゲル薬物送達インプラント
WO2016100392A1 (en) * 2014-12-15 2016-06-23 The Johns Hopkins University Sunitinib formulations and methods for use thereof in treatment of ocular disorders
JP6479485B2 (ja) 2015-01-15 2019-03-06 大内新興化学工業株式会社 眼疾患治療用ナノ粒子製剤
CN107206099A (zh) 2015-01-20 2017-09-26 约翰霍普金斯大学 用于持续释放抗青光眼剂以控制眼内压的组合物
BR112017023762A2 (pt) 2015-05-05 2018-07-31 Psivida Us, Inc. formulações de depósito injetáveis
EP4279064A3 (en) 2015-05-12 2024-02-28 Incept, LLC Drug delivery from hydrogels
US10617563B2 (en) 2015-07-22 2020-04-14 Incept, Llc Coated implants
WO2017091749A1 (en) 2015-11-25 2017-06-01 Incept, Llc Shape changing drug delivery devices and methods

Similar Documents

Publication Publication Date Title
JP2018500394A5 (ja)
JP2017537985A5 (ja)
RU2017123358A (ru) Составы на основе сунитиниба и способы их применения для лечения глазных заболеваний
US20230126007A1 (en) Nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents
Elzoghby et al. Zein-based nanocarriers as potential natural alternatives for drug and gene delivery: focus on cancer therapy
Sun et al. Sustained release of brimonidine from a new composite drug delivery system for treatment of glaucoma
Haggag et al. Preparation and in vivo evaluation of insulin-loaded biodegradable nanoparticles prepared from diblock copolymers of PLGA and PEG
Lai et al. Overview of the preparation of organic polymeric nanoparticles for drug delivery based on gelatine, chitosan, poly (d, l-lactide-co-glycolic acid) and polyalkylcyanoacrylate
Hathout et al. Gelatin-based particulate systems in ocular drug delivery
ES2821526T3 (es) Microesferas o micropartículas biodegradables o bioerosionables de liberación con el tiempo en suspensión en una formulación de fármaco inyectable de formación de depósito solidificante
WO2008157614A3 (en) Sustained intraocular delivery of drugs from biodegradable polymeric microparticles
NZ595294A (en) Intraocular sustained release drug delivery systems and methods for treating ocular conditions
JP2011528656A5 (ja)
JP2018533596A5 (ja)
Michalak et al. Polymeric nanoparticles–a novel solution for delivery of antimicrobial agents
Patel et al. Biodegradable polymers: Emerging excipients for the pharmaceutical and medical device industries
JP2018503736A5 (ja)
JP2011503213A5 (ja)
Park et al. Enhanced ocular efficacy of topically-delivered dorzolamide with nanostructured mucoadhesive microparticles
RU2018105494A (ru) Улучшенные системы доставки наночастиц
JP2015520241A5 (ja)
Gavini et al. Biodegradable microspheres as intravitreal delivery systems for prolonged drug release. What is their eminence in the nanoparticle era?
US20200023332A1 (en) Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation
JPWO2019088214A1 (ja) 徐放性医薬組成物
Moayedian et al. Combined effects of PEGylation and particle size on uptake of PLGA particles by macrophage cells